Cargando…

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review

BACKGROUND: In the absence of highly effective antiviral therapies against SARS-CoV-2, it is crucial to counter the known pathophysiological causes of severe COVID-19. Evaluating the efficacy existing drugs may expedite the development of such therapeutics. Severe COVID-19 is largely the result of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, Avi Gurion, Siegel, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643559/
https://www.ncbi.nlm.nih.gov/pubmed/33194450
http://dx.doi.org/10.7717/peerj.10322

Ejemplares similares